https://scholars.lib.ntu.edu.tw/handle/123456789/568287
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Asahina Y. | en_US |
dc.contributor.author | CHUN-JEN LIU | en_US |
dc.contributor.author | Gane E. | en_US |
dc.contributor.author | Itoh Y. | en_US |
dc.contributor.author | Kawada N. | en_US |
dc.contributor.author | Ueno Y. | en_US |
dc.contributor.author | Youn J. | en_US |
dc.contributor.author | Wang C.-Y. | en_US |
dc.contributor.author | Llewellyn J. | en_US |
dc.contributor.author | Matsuda T. | en_US |
dc.contributor.author | Gaggar A. | en_US |
dc.contributor.author | Mo H. | en_US |
dc.contributor.author | Dvory-Sobol H. | en_US |
dc.contributor.author | Crans G. | en_US |
dc.contributor.author | Chuang W.-L. | en_US |
dc.contributor.author | PEI-JER CHEN | en_US |
dc.contributor.author | Enomoto N. | en_US |
dc.date.accessioned | 2021-07-03T03:33:22Z | - |
dc.date.available | 2021-07-03T03:33:22Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1386-6346 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85089292743&doi=10.1111%2fhepr.13546&partnerID=40&md5=4effe542895a7e17e332c7aaf1461c86 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/568287 | - |
dc.description.abstract | Aim: The combination of ledipasvir and sofosbuvir (LDV/SOF) has been approved for the treatment of various hepatitis C virus (HCV) genotypes across many countries. This article presents an integrated analysis of three prospective phase II/III trials in the Asia-Pacific region to evaluate the efficacy and safety of 12?weeks of LDV/SOF in HCV genotype 2 patients without cirrhosis or with compensated cirrhosis. Methods: A total of 200 patients were included in the integrated analysis. The primary end-point was the rate of sustained virologic response for 12?weeks after the end of therapy (SVR12), analyzed by fibrosis stage, treatment history, HCV genotype subtype, and presence of baseline resistance-associated substitutions (RAS). Safety was evaluated by adverse events and laboratory abnormalities. Results: Twelve weeks of treatment with LDV/SOF was associated with high SVR12 rates (overall 98%) in patients with genotype 2 HCV, irrespective of fibrosis stage, treatment history, genotype 2 subtype, and presence of baseline non-structural protein 5A resistance-associated substitution (NS5A RAS), and LDV/SOF was well tolerated. Conclusions: Twelve weeks of treatment with LDV/SOF provides a highly effective and safe treatment for patients with genotype 2 HCV, including those with advanced fibrosis. As a ribavirin-free and protease inhibitor-free regimen with minimal on-treatment monitoring requirements, LDV/SOF can potentially play a crucial role in achieving the WHO's goal of HCV elimination. ? 2020 The Authors. Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology | - |
dc.publisher | Blackwell Publishing Ltd | - |
dc.relation.ispartof | Hepatology Research | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | ledipasvir; sofosbuvir; adult; Article; Child Pugh score; chronic hepatitis B; chronic hepatitis C; controlled study; drug efficacy; drug safety; drug tolerability; drug withdrawal; fatigue; female; genotype; headache; Hepatitis C virus genotype 2; human; limit of quantitation; liver fibrosis; major clinical study; male; middle aged; multicenter study; nausea; phase 3 clinical trial; priority journal; randomized controlled trial; relapse; rheumatoid arthritis; rhinopharyngitis; sustained virologic response | - |
dc.title | Twelve weeks of ledipasvir/sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection: Integrated analysis of three clinical trials | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1111/hepr.13546 | - |
dc.identifier.scopus | 2-s2.0-85089292743 | - |
dc.relation.pages | 1109-1117 | - |
dc.relation.journalvolume | 50 | - |
dc.relation.journalissue | 10 | - |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.orcid | 0000-0002-6202-0993 | - |
crisitem.author.orcid | 0000-0001-8316-3785 | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。